PMID- 30050765
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 2218-6751 (Print)
IS  - 2226-4477 (Electronic)
IS  - 2218-6751 (Linking)
VI  - 7
IP  - 3
DP  - 2018 Jun
TI  - The importance of incorporating smoking cessation into lung cancer screening.
PG  - 272-280
LID - 10.21037/tlcr.2018.05.03 [doi]
AB  - Lung cancer is the leading cause of cancer-related death in the United States 
      (U.S.) and is the second most common non-skin cancer among men and women, 
      accounting for about 30% of cancer-related deaths. There is clear and 
      accumulating evidence that continued tobacco use has multiple adverse effects on 
      cancer treatment outcomes, including greater probability of recurrence, second 
      primary malignancies, reduced survival, greater symptom burden, and poorer 
      quality of life (QOL). Recent findings suggest an avenue to significantly 
      mitigate the impact of smoking on lung cancer mortality rates through the use of 
      low-dose computed tomography (LDCT) lung cancer screening. Based on the reviewed 
      evidence (type B), the U.S. Preventive Services Task Force (USPSTF) guidelines of 
      2015 recommend screening combined with smoking cessation interventions for 
      high-risk heavy smokers and recent quitters. These practice changes offer 
      opportunities to develop novel smoking cessation strategies tailored to highly 
      specific settings that aim to amplify the survivorship gains expected from 
      screening alone. However, there is a paucity of research and data that speaks to 
      the feasibility and efficacy of providing smoking cessation treatment 
      specifically within the context of the LDCT lung cancer screening environment. 
      While some studies have attempted to characterize the parameters within which 
      smoking cessation interventions should be implemented in this context, further 
      research is needed to explore relevant factors such as the format, components, 
      and timing of interventions, as well as the influence of risk perceptions and 
      results of the screening itself on motivation and ability to quit smoking.
FAU - Minnix, Jennifer Anne
AU  - Minnix JA
AD  - Department of Behavioral Science, University of Texas MD Anderson Cancer Center, 
      Houston, TX, USA.
FAU - Karam-Hage, Maher
AU  - Karam-Hage M
AD  - Department of Behavioral Science, University of Texas MD Anderson Cancer Center, 
      Houston, TX, USA.
FAU - Blalock, Janice A
AU  - Blalock JA
AD  - Department of Behavioral Science, University of Texas MD Anderson Cancer Center, 
      Houston, TX, USA.
FAU - Cinciripini, Paul M
AU  - Cinciripini PM
AD  - Department of Behavioral Science, University of Texas MD Anderson Cancer Center, 
      Houston, TX, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - China
TA  - Transl Lung Cancer Res
JT  - Translational lung cancer research
JID - 101646875
EIN - Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S303. PMID: 30393629
PMC - PMC6037969
OTO - NOTNLM
OT  - Smoking
OT  - low-dose computer tomography (LDCT)
OT  - lung cancer screening
OT  - review
OT  - smoking cessation
COIS- Conflicts of Interest: The authors have no conflicts of interest to declare.
EDAT- 2018/07/28 06:00
MHDA- 2018/07/28 06:01
PMCR- 2018/06/01
CRDT- 2018/07/28 06:00
PHST- 2018/07/28 06:00 [entrez]
PHST- 2018/07/28 06:00 [pubmed]
PHST- 2018/07/28 06:01 [medline]
PHST- 2018/06/01 00:00 [pmc-release]
AID - tlcr-07-03-272 [pii]
AID - 10.21037/tlcr.2018.05.03 [doi]
PST - ppublish
SO  - Transl Lung Cancer Res. 2018 Jun;7(3):272-280. doi: 10.21037/tlcr.2018.05.03.